The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Uveal melanoma: From diagnosis to treatment and the science in between
Open accessAbstract
Melanomas of the choroid, ciliary body, and iris of the eye are collectively known as uveal melanomas. These cancers represent 5% of all melanoma diagnoses in the United States, and their age‐adjusted risk is 5 per 1 million population. These less frequent melanomas are dissimilar to their more common cutaneous melanoma relative, with differing risk factors, primary treatment, anatomic spread, molecular changes, and responses to systemic therapy. Once uveal melanoma becomes metastatic, therapy options are limited and are often extrapolated from cutaneous melanoma therapies despite the routine exclusion of patients with uveal melanoma from clinical trials. Clinical trials directed at uveal melanoma have been completed or are in progress, and data from these well designed investigations will help guide future directions in this orphan disease. Cancer 2016;122:2299–2312. © 2016 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi
Van Raamsdonk, C. D., Bezrookove, V., Green, G., Bauer, J., Gaugler, L., O’Brien, J. M., Simpson, E. M., Barsh, G. S., & Bastian, B. C. (2009) · Nature · doi:10.1038/nature07586 · Cited by 1,623
Mutations in GNA11 in Uveal Melanoma
Van Raamsdonk, C. D., Griewank, K. G., Crosby, M. B., Garrido, M. C., Vemula, S., Wiesner, T., Obenauf, A. C., Wackernagel, W., Green, G., Bouvier, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1000584 · Cited by 1,476
Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas
Harbour, J. W., Onken, M. D., Roberson, E. D. O., Duan, S., Cao, L., Worley, L. A., Council, M. L., Matatall, K. A., Helms, C., & Bowcock, A. M. (2010) · Science · doi:10.1126/science.1194472 · Cited by 1,462
Uveal Melanoma: Trends in Incidence, Treatment, and Survival
Singh, A. D., Turell, M. E., & Topham, A. K. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.01.040 · Cited by 1,267
(2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.969 · Cited by 771
Feng, X., Degese, M. S., Iglesias-Bartolome, R., Vaque, J. P., Molinolo, A. A., Rodrigues, M., Zaidi, M. R., Ksander, B. R., Merlino, G., Sodhi, A., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.016 · Cited by 563
Martin, M., Maßhöfer, L., Temming, P., Rahmann, S., Metz, C., Bornfeld, N., van de Nes, J., Klein-Hitpass, L., Hinnebusch, A. G., Horsthemke, B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2674 · Cited by 542
Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma
Harbour, J. W., Roberson, E. D. O., Anbunathan, H., Onken, M. D., Worley, L. A., & Bowcock, A. M. (2013) · Nature Genetics · doi:10.1038/ng.2523 · Cited by 516
Onken, M. D., Worley, L. A., Char, D. H., Augsburger, J. J., Correa, Z. M., Nudleman, E., Aaberg, T. M., Altaweel, M. M., Bardenstein, D. S., Finger, P. T., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.017 · Cited by 506
Mutant Gq/11 Promote Uveal Melanoma Tumorigenesis by Activating YAP
Yu, F.-X., Luo, J., Mo, J.-S., Liu, G., Kim, Y. C., Meng, Z., Zhao, L., Peyman, G., Ouyang, H., Jiang, W., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.04.017 · Cited by 463
SF3B1 Mutations Are Associated with Alternative Splicing in Uveal Melanoma
Furney, S. J., Pedersen, M., Gentien, D., Dumont, A. G., Rapinat, A., Desjardins, L., Turajlic, S., Piperno-Neumann, S., de la Grange, P., Roman-Roman, S., et al. (2013) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0330 · Cited by 434
Carvajal, R. D., Sosman, J. A., Quevedo, J. F., Milhem, M. M., Joshua, A. M., Kudchadkar, R. R., Linette, G. P., Gajewski, T. F., Lutzky, J., Lawson, D. H., et al. (2014) · JAMA · doi:10.1001/jama.2014.6096 · Cited by 433
The Prognostic Value of Tumor Blood Vessel Morphology in Primary Uveal Melanoma
Folberg, R., Rummelt, V., Parys-Van Ginderdeuren, R., Hwang, T., Woolson, R. F., Pe'er, J., & Gruman, L. M. (1993) · Ophthalmology · doi:10.1016/s0161-6420(93)31470-3 · Cited by 421
Survival of Patents with Metastases from Uveal Melanoma
Gragoudas, E. S., Egan, K. M., Seddon, J. M., Glynn, R. J., Walsh, S. M., Finn, S. M., Munzenrider, J. E., & Spar, M. D. (1991) · Ophthalmology · doi:10.1016/s0161-6420(91)32285-1 · Cited by 368
Bedikian, A. Y., Legha, S. S., Mavligit, G., Carrasco, C. H., Khorana, S., Plager, C., Papadopoulos, N., & Benjamin, R. S. (1995) · Cancer · doi:10.1002/1097-0142(19951101)76:9<1665::aid-cncr2820760925>3.0.co;2-j · Cited by 335
BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs
Carbone, M., Ferris, L. K., Baumann, F., Napolitano, A., Lum, C. A., Flores, E. G., Gaudino, G., Powers, A., Bryant-Greenwood, P., Krausz, T., et al. (2012) · Journal of Translational Medicine · doi:10.1186/1479-5876-10-179 · Cited by 323
Histone Deacetylase Inhibitors Induce Growth Arrest and Differentiation in Uveal Melanoma
Landreville, S., Agapova, O. A., Matatall, K. A., Kneass, Z. T., Onken, M. D., Lee, R. S., Bowcock, A. M., & Harbour, J. W. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0946 · Cited by 289
Zimmer, L., Vaubel, J., Mohr, P., Hauschild, A., Utikal, J., Simon, J., Garbe, C., Herbst, R., Enk, A., Kämpgen, E., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0118564 · Cited by 269
Luke, J. J., Callahan, M. K., Postow, M. A., Romano, E., Ramaiya, N., Bluth, M., Giobbie‐Hurder, A., Lawrence, D. P., Ibrahim, N., Ott, P. A., et al. (2013) · Cancer · doi:10.1002/cncr.28282 · Cited by 192
Recent developments in prognostic and predictive testing in uveal melanoma
Field, M. G., & Harbour, J. W. (2014) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000051 · Cited by 167
Clinical and Cytogenetic Analyses in Uveal Melanoma
Kilic, E., van Gils, W., Lodder, E., Beverloo, H. B., van Til, M. E., Mooy, C. M., Paridaens, D., de Klein, A., & Luyten, G. P. M. (2006) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.06-0101 · Cited by 163
Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
Danielli, R., Ridolfi, R., Chiarion‐Sileni, V., Queirolo, P., Testori, A., Plummer, R., Boitano, M., Calabrò, L., Rossi, C. D., Giacomo, A. M. D., et al. (2011) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-011-1089-0 · Cited by 146
Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
Maio, M., Danielli, R., Chiarion‐Sileni, V., Pigozzo, J., Parmiani, G., Ridolfi, R., Rosa, F. D., Vecchio, M. D., Guardo, L. D., Queirolo, P., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt376 · Cited by 142
Systemic treatment of metastatic uveal melanoma: review of literature and future perspectives
Buder, K., Gesierich, A., Gelbrich, G., & Goebeler, M. (2013) · Cancer Medicine · doi:10.1002/cam4.133 · Cited by 132
Dono, M., Angelini, G., Cecconi, M., Amaro, A. A., Esposito, A. I., Mirisola, V., Maric, I., Lanza, F. B., Nasciuti, F., Viaggi, S., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2013.804 · Cited by 124
Patel, K., Sullivan, K. L., Berd, D., Mastrangelo, M. J., Shields, C. L., Shields, J. A., & Sato, T. (2005) · Melanoma Research · doi:10.1097/00008390-200508000-00011 · Cited by 120
Crizotinib, a c-Met Inhibitor, Prevents Metastasis in a Metastatic Uveal Melanoma Model
Surriga, O., Rajasekhar, V. K., Ambrosini, G., Dogan, Y., Huang, R., & Schwartz, G. K. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0499 · Cited by 118
Emerging Insights into the Molecular Pathogenesis of Uveal Melanoma
Landreville, S., Agapova, O. A., & Harbour, J. W. (2008) · Future Oncology · doi:10.2217/14796694.4.5.629 · Cited by 112
The use of pembrolizumab for the treatment of metastatic uveal melanoma
Kottschade, L. A., McWilliams, R. R., Markovic, S. N., Block, M. S., Villasboas, J. C., Pham, A., Esplin, B. L., & Dronca, R. S. (2016) · Melanoma Research · doi:10.1097/cmr.0000000000000242 · Cited by 111
Mode of presentation and time to treatment of uveal melanoma in Finland
Eskelin, S., & Kivela, T. (2002) · British Journal of Ophthalmology · doi:10.1136/bjo.86.3.333 · Cited by 109
Valsecchi, M. E., Terai, M., Eschelman, D. J., Gonsalves, C. F., Chervoneva, I., Shields, J. A., Shields, C. L., Yamamoto, A., Sullivan, K. L., Laudadio, M., et al. (2015) · Journal of Vascular and Interventional Radiology · doi:10.1016/j.jvir.2014.11.037 · Cited by 98
Schmittel, A. H., Schmidt‐Hieber, M., Martus, P., Bechrakis, N., Schuster, R., Siehl, J., Foerster, M. H., Thiel, E., & Keilholz, U. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl309 · Cited by 93
Hofmann, U. B., Vetter, C. S., Houben, R., & Becker, J. C. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2243 · Cited by 91
Bhatia, S., Moon, J., Margolin, K. A., Weber, J. S., Lao, C. D., Othus, M. K. D., Aparicio, A. M., Ribas, A., & Sondak, V. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0048787 · Cited by 89
Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin
Tarhini, A. A., Frankel, P. H., Margolin, K. A., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1463 · Cited by 87
A pilot study of sunitinib malate in patients with metastatic uveal melanoma
Mahipal, A., Tijani, L., Chan, K. R., Laudadio, M., Mastrangelo, M. J., & Sato, T. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e328358b373 · Cited by 85
Modeling of Human Uveal Melanoma in Zebrafish Xenograft Embryos
van der Ent, W., Burrello, C., Teunisse, A. F. A. S., Ksander, B. R., van der Velden, P. A., Jager, M. J., Jochemsen, A. G., & Snaar-Jagalska, E. B. (2014) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15202 · Cited by 84
Gene Expression Profiling in Uveal Melanoma: Two Regions on 3p Related to Prognosis
van Gils, W., Lodder, E. M., Mensink, H. W., Kılıç, E., Naus, N. C., Brüggenwirth, H. T., van IJcken, W. F. J., Paridaens, D. A., Luyten, G. P. M., & de Klein, A. (2008) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.08-2033 · Cited by 83
Kelderman, S., van der Kooij, M. K., van den Eertwegh, A. J. M., Soetekouw, P. M. M. B., Jansen, R. L. H., van den Brom, R. R. H., Hospers, G. A. P., Haanen, J. B. A. G., Kapiteijn, E., & Blank, C. U. (2013) · Acta Oncologica · doi:10.3109/0284186x.2013.786839 · Cited by 78
Phase II evaluation of temozolomide in metastatic choroidal melanoma
Bedikian, A. Y., Papadopoulos, N., Plager, C., Eton, O. E., & Ring, S. E. (2003) · Melanoma Research · doi:10.1097/00008390-200306000-00013 · Cited by 77
Bedikian, A. Y., Legha, S. S., Mavligit, G. M., et al. (1996) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)70300-9 · Cited by 67
Prevalence of germline BAP 1 mutation in a population‐based sample of uveal melanoma cases
Aoude, L. G., Vajdic, C. M., Kricker, A., Armstrong, B. K., & Hayward, N. K. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12046 · Cited by 62
Ipilimumab activity in advanced uveal melanoma
Khattak, M. A., Fisher, R. A., Hughes, P., Gore, M. E., & Larkin, J. (2012) · Melanoma Research · doi:10.1097/cmr.0b013e32835b554f · Cited by 60
Targeting Bcl-2/Bcl-XL Induces Antitumor Activity in Uveal Melanoma Patient-Derived Xenografts
Némati, F., de Montrion, C., Lang, G., Kraus‐Berthier, L., Carita, G., Sastre‐Garau, X., Berniard, A., Vallerand, D., Geneste, O., de Plater, L., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080836 · Cited by 59
Pan, H., Jia, R., Zhang, L., Xu, S., Wu, Q., Song, X., Zhang, H., Ge, S., Xu, X. L., & Fan, X. (2015) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2015.01.001 · Cited by 56
Penel, N., Delcambre, C., Durando, X., Clisant, S., Hebbar, M., Négrier, S., Fournier, C., Isambert, N., Mascarelli, F., & Mouriaux, F. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9143-2 · Cited by 56
A phase II study of gefitinib in patients with metastatic melanoma
Patel, S. P., Kim, K. B., Papadopoulos, N. E., Hwu, W., Hwu, P., Prieto, V. G., Bar‐Eli, M., Zigler, M., Dobroff, A. S., Bronstein, Y., et al. (2011) · Melanoma Research · doi:10.1097/cmr.0b013e3283471073 · Cited by 45
Self-citationAnalysis of BAP1 Germline Gene Mutation in Young Uveal Melanoma Patients
Cebulla, C. M., Binkley, E. M., Pilarski, R., Massengill, J. B., Rai, K., Liebner, D. A., Marino, M. J., Singh, A. D., & Abdel‐Rahman, M. H. (2015) · Ophthalmic Genetics · doi:10.3109/13816810.2015.1010734 · Cited by 44
Phase II study of thalidomide in patients with metastatic malignant melanoma
Reiriz, A. B., Richter, M. F., Fernandes, S. A., Cancela, A. I. N., Costa, T. D., Leone, L., & Schwartsmann, G. (2004) · Melanoma Research · doi:10.1097/00008390-200412000-00014 · Cited by 43
Tg(Grm1) transgenic mice: A murine model that mimics spontaneous uveal melanoma in humans?
Schiffner, S., Braunger, B. M., de Jel, M. M., Coupland, S. E., Tamm, E. R., & Bosserhoff, A. (2014) · Experimental Eye Research · doi:10.1016/j.exer.2014.07.009 · Cited by 41
Luscan, A., Just, P., Briand‐Suleau, A., Roziers, C. B. D., Goussard, P., Nitschké, P., Vidaud, M., Avril, M.-F., Terris, B., & Pasmant, É. (2014) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2014-305371 · Cited by 36
YAP as oncotarget in uveal melanoma
Yu, F., Zhang, K., & Guan, K. (2014) · Oncoscience · doi:10.18632/oncoscience.57 · Cited by 14
Zeldis, J. B., Heller, C. K., Seidel, G., Yuldasheva, N., Stirling, D., Shutack, Y., & Libutti, S. K. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.e20012 · Cited by 6
Cited by
Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma
Robertson, A. G., Shih, J., Yau, C., Gibb, E. A., Oba, J., Mungall, K. L., Hess, J. M., Uzunangelov, V., Walter, V., Danilova, L., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.07.003 · Cited by 887
Self-citationUveal melanoma: epidemiology, etiology, and treatment of primary disease
Krantz, B. A., Dave, N., Komatsubara, K. M., Marr, B. P., & Carvajal, R. D. (2017) · Clinical Ophthalmology · doi:10.2147/opth.s89591 · Cited by 402
Han, H., Li, S., Xu, M., Zhong, Y., Fan, W., Xu, J., Zhou, T., Ji, J., Ye, J., & Yao, K. (2023) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2023.114770 · Cited by 322
Uveal melanoma: Towards a molecular understanding
Smit, K. N., Jager, M. J., de Klein, A., & Kiliҫ, E. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100800 · Cited by 264
Metadata
- Authors
- Chattopadhyay, C., Kim, D. W., Gombos, D. S., Oba, J., Qin, Y., Williams, M. D., Esmaeli, B., Grimm, E. A., Wargo, J. A., Woodman, S. E., & Patel, S. P.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2016-03-15
- Volume
- 122
- Issue
- 15
- Pages
- 2299-2312
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2300492004
- Cited by
- 443
- References
- 54
- FWCI
- 25.74
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.